KPTI vs KYNB

Karyopharm Therapeutics Inc. vs Kyntra Bio, Inc. — Valuation Comparison 2026

KPTI

Pharmaceutical Preparations
Karyopharm Therapeutics Inc.
Quality
5.1
out of 10
Value Trap
30
LOW
Price
$9.10
Last close
Models
7/13
Active
VS

KYNB

Pharmaceutical Preparations
Kyntra Bio, Inc.
Quality
5.3
out of 10
Value Trap
47
WARN
Price
$6.90
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType KPTI Fair ValueKPTI Upside KYNB Fair ValueKYNB Upside
Bayesian DCF Intrinsic $3.13 -65.6% $16.17 +132.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $16.33 +136.6%
PWERM Option-Based $23.88 +162.4% $17.05 +147.2%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for KPTI vs KYNB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KPTI vs KYNB — Which Stock Is More Undervalued?

KYNB scores higher with a 5.3/10 quality rating vs KPTI's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Karyopharm Therapeutics Inc. (KPTI) and Kyntra Bio, Inc. (KYNB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KPTI currently trades at $9.10 with a QOC of 5.1/10, while KYNB trades at $6.90 with a QOC of 5.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).